Product Description
For the treatment of anemia in patients with chronic kidney disease of stage III-IV in systemic diseases (Sourced from: https://pubmed.ncbi.nlm.nih.gov/17684963/)
Mechanisms of Action: ESA Activator
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intravenous,Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hepatic Insufficiency|Kidney Failure, Chronic|Acute-On-Chronic Liver Failure|End Stage Liver Disease|Liver Failure, Acute|Brain Death|Acute Respiratory Distress Syndrome|Hypothermia|Hypoxia, Brain
Phase 2: Aortic Diseases|Hypoplastic Left Heart Syndrome|Amyotrophic Lateral Sclerosis|Transposition of Great Vessels|Stroke
Phase 1: Urological Manifestations|Spinal Injuries
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| PAEAN | P3 |
Active, not recruiting |
Acute Respiratory Distress Syndrome|Hypoxia, Brain|Brain Death|Hypothermia |
2021-03-31 |
2025-06-09 |
Treatments |
|
| AiME - 04 | P3 |
Completed |
Kidney Failure, Chronic |
2015-02-13 |
2019-03-19 |
Primary Completion Date|Study Completion Date |
|
| AiME - 03 | P3 |
Completed |
Kidney Failure, Chronic |
2015-01-02 |
2019-03-19 |
Treatments |
|
| ACLF | P3 |
Completed |
Hepatic Insufficiency|Liver Failure, Acute|End Stage Liver Disease|Acute-On-Chronic Liver Failure |
2013-01-01 |
2019-03-19 |
Treatments |
|
| R21HD5550101 | P2 |
Completed |
Hypoplastic Left Heart Syndrome|Transposition of Great Vessels|Aortic Diseases |
2012-09-01 |
2020-02-09 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| GCSFEPO_01 | P2 |
Completed |
Stroke|Amyotrophic Lateral Sclerosis |
2009-03-01 |
2019-03-21 |
Treatments |
|
| TETRAM2 | P1 |
Withdrawn |
Urological Manifestations|Spinal Injuries |
None |
2019-03-21 |
Treatments |